Author Interviews, Pharmacology, Schizophrenia / 31.10.2018
Phase 3 Study of Novel, Once-Daily, Antipsychotic Drug Candidate for Schizophrenia
MedicalResearch.com Interview with:
Jelena Kunovac, M.D., M.S.
Founder and Chief Executive
Chief Medical Officer
Altea Research
Las Vegas, Nevada
MedicalResearch.com: What is the background for this study?
Response: We conducted the study to confirm that the addition of samidorphan to olanzapine does not have an effect on the antipsychotic efficacy of olanzapine in subjects with an acute exacerbation of schizophrenia.
(more…)